这不是说这些公司不好。问题在于，当所有人都在同一个方向押注，并且已经押了两年之后，投资者需要开始认真 思考一个问题： 从现在这个估值起点，未来三到五年，这笔投资的复合回报率还能有多少？ 这个问题，会把市场投资人引向那些还没怎么涨、但已迎来价值拐点的公司。 本文约稿作者 | 贝隆行业研究 数据支持 | 勾股 大数 据（www.gogudata.com） 新氧（SY.US）的财报数据，或许提供了一个值得观察的样本。 3月25日，新氧交出了2025年第四季度财报。财报发布后当日公司股价收盘大涨近10%，市场用真金白银给出了 第一时间的反馈。 有一类投资机会，从来不在聚光灯下出现。 2025年，AI算力、半导体、机器人——这些词汇主导了财经媒体的头版，也主导了大多数机构的仓位配置。英伟 达的市盈率一度超过40倍，部分国内AI概念股的市销率（P/S）更是高达数十倍。市场给"未来"标出了令人眩晕 的价格。 资本市场的定价逻辑从来不复杂： 估值越低，未来回报的空间越大。而财报发布当日股价的积极反应，恰恰说明 市场已经开始重新审视这份答卷。 01 十倍股的数学：为什么高PE是回报的天敌 在讨论任何具体公司之前，有必要先厘清一 ...

Core Insights - The valuation anchor for the medical beauty industry is shifting from high-margin approvals to user-centric metrics such as repurchase rates, single-store models, and scalability [2][9][42] Group 1: Market Dynamics - The recent launch of New Oxygen's "Miracle Youth" series at a price point of 2999 yuan has made youth-enhancing injections more accessible to the general public, indicating a potential shift in the traditional pricing structure [4][9] - The price of youth-enhancing injections has historically been high, with some products priced significantly above gold, but the introduction of lower-priced options suggests a loosening of the previous pricing power held by manufacturers [7][11] - The Chinese medical beauty market is experiencing a surge in competition, with multiple youth-enhancing products receiving approvals, leading to a more fragmented market [23][42] Group 2: Consumer Behavior Changes - The primary consumer base for medical beauty has shifted from affluent older clients to urban white-collar workers who are more price-sensitive and seek value for money [28][29] - Consumers are increasingly relying on social media platforms for information, preferring transparent pricing and verifiable product efficacy over high-priced luxury experiences [29][30] - The demand for standardized and replicable services is growing, pushing providers to adapt their business models to focus on product quality and customer retention [31][32] Group 3: Industry Structure and Future Outlook - The medical beauty industry is moving towards a decentralized model where manufacturers are no longer the sole price setters, allowing service providers to create their own product combinations [35][46] - The shift in pricing and consumer logic is expected to impact capital markets, with investors beginning to focus on user value metrics rather than just high margins from manufacturers [40][42] - Successful models in other sectors, such as chain medical services, demonstrate that scale and user retention can lead to valuation premiums, suggesting a similar trajectory for the medical beauty industry [43][45]